Medicine & Health

IF an AI-engineered human CYP27A1 variant — redesigned via RFdiffusion backbone remodeling of the B-C and F-G loop substrate-access channels and ProteinMPNN sequence optimization to rigidify the active-site pocket around the 7-keto moiety (targeting residues proximal to Leu369, Val373, and Leu497 identified in PDB: 3M2Q), packaged into AAV8 at 3×10¹¹ vector genomes per mouse under the disease-responsive macrophage scavenger receptor 1 (MSR1/CD204) promoter — is delivered via tail-vein injection to 12-week-old male ApoE⁻/⁻ mice that have been on Western diet for 8 weeks prior to injection (established foam-cell plaque stage), then continued on Western diet for 8 weeks post-injection with sacrifice at week 24,

THEN aortic macrophages isolated by collagenase digestion and CD11b⁺ magnetic sorting will show ≥60% reduction in intracellular 7-ketocholesterol (7KC) by isotope-dilution LC-MS/MS, accompanied by a ≥30% increase in the 7KC-27OH metabolite, a ≥25% reduction in en face aortic Oil Red O surface area, a ≥20% increase in Picrosirius Red-quantified collagen content, and a ≥30% reduction in CD68⁺ plaque macrophage area in aortic root cross-sections relative to AAV8-MSR1-GFP control mice,

BECAUSE the following causal chain operates:

1. Accumulated intracellular 7KC in plaque foam cells is a primary driver of ongoing lysosomal membrane permeabilization, ER stress, and NLRP3 inflammasome activation — not merely a downstream marker of disease — making it a bona fide accumulated damage substrate amenable to enzymatic repair. Wild-type CYP27A1 already processes 7KC with a

Background

Drug-free remission (DFR) in rheumatoid arthritis remains poorly predicted by conventional models. Standard Cox regression treats all patients as eventually relapsing, ignoring the cured fraction — patients who achieve sustained DFR indefinitely. Meanwhile, pharmacogenomic markers (HLA-DRB1 shared epitope, CYP3A4/CYP2C19 metabolizer status, NAT2 acetylator phenotype) interact with treatment history in time-dependent ways that static models cannot capture.

Hypothesis

A cure-mixture survival model (Berkson-Gage framework) with time-varying pharmacogenomic covariates will significantly outperform standard Cox and random survival forest models in predicting which RA patients can successfully discontinue biologics without relapse.

Specifically:

1. The cure fraction π(x) is modeled via logistic regression on baseline HLA-DRB1 shared epitope allele dosage, ACPA status, and cumulative biologic exposure duration
2. The susceptible subgroup survival function S(t|uncured) follows a flexible Royston-Parmar spline model with time-varying coefficients for CYP metabolizer status × biologic type interaction
3. A Bayesian estimation framework with weakly informative priors (half-Cauchy on variance components) provides posterior distributions over cure probability per patient

Testable Predictions

IF a dual-modality lysosomal repair intervention—comprising (1) subretinal or intravitreal AAV9-mediated overexpression of the V-ATPase subunit ATP6V0D1 to restore lysosomal acidification, co-administered with (2) lysosome-targeted PLGA acidic nanoparticles (aNPs) encapsulating a thermostable bacterial bisretinoid-oxidizing enzyme (specifically a carotenoid-cleaving dioxygenase, CCD, from Novosphingobium sp. or structurally analogous genus, engineered with a mannose-6-phosphate (M6P) lysosomal-targeting signal and an acidic pH activity optimum) — is delivered to aged female C57BL/6J mice (22–24 months) and/or ABCA4−/− mice (12–18 months) with established bisretinoid/lipofuscin burden in the RPE,

THEN a measurable reduction in RPE autofluorescent aggregate burden (≥30% decrease in fundus autofluorescence intensity and ≥25% reduction in HPLC-quantified A2E/bis-A2E levels within 12 weeks), accompanied by ≥0.35 unit decrease in lysosomal pH and ≥40% restoration of Cathepsin D proteolytic activity relative to aged vehicle-injected controls, will be observed,

BECAUSE the following mechanistic chain operates:

1. Age-associated lysosomal alkalinization (~pH 5.5–6.5 in aged RPE vs. ~4.5–5.0 in young RPE) directly drives accumulation of autofluorescent granules, as demonstrated by the finding that pharmacologically elevating lysosomal pH to >6.0 in RPE cells is sufficient to induce lipofuscin-like aggregate formation, and that restoration of acidification with PLGA/m-tartaric acid aNPs within 24 hours rescues Cathepsin D activity and reduces granule formation (im

Abstract

Recent advances in biomaterials and bioelectronics suggest the potential for a smart, bioactive hemostatic wound dressing. This study proposes a next-generation square honey-jelly bee extract bio-plate integrated with a programmable microchip capable of measuring wound depth, bleeding severity, blood loss, and correlating these parameters with the patient’s heart rate and blood pressure. The bio-plate combines natural bee-derived compounds—Royal Jelly, Honey, and Propolis—embedded in a chitosan-alginate scaffold, providing rapid hemostasis, antimicrobial protection, and tissue healing. The embedded microchip continuously collects real-time physiological data, enabling calculation of bleeding velocity, wound severity index, and estimated healing progression. This innovation represents a convergence of natural biomaterials, smart biosensing, and regenerative medicine, potentially transforming trauma and emergency care.

Background

Severe bleeding remains a major challenge in trauma and emergency medicine. Conventional wound dressings focus on compression and absorption but cannot actively monitor physiological response or dynamically adapt to bleeding severity. Honey-derived compounds have antimicrobial, anti-inflammatory, and clot-promoting properties, while royal jelly and propolis accelerate tissue repair. By integrating these bioactive compounds with embedded digital biosensing, it is possible to create a wound dressing that not only accelerates clotting but also quantifies the patient’s physiological response in real time. Smart biosensors within the pla

Hypothesis

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) progression is currently detected by serial HRCT and pulmonary function tests (FVC decline ≥10%), but these measures lag behind actual parenchymal injury. We hypothesize that circulating cell-free DNA (cfDNA) fragments bearing alveolar type II (AT2) cell-specific methylation patterns — detectable via targeted bisulfite sequencing of SFTPC, SFTPB, and NKX2-1 promoter regions — will identify active AT2 apoptosis and predict HRCT-confirmed ILD progression 6–12 months before conventional radiographic or spirometric deterioration.

Rationale

AT2 cells are the primary regenerative progenitors of the alveolar epithelium. In SSc-ILD, fibrotic remodeling is preceded by AT2 injury and apoptosis, releasing cfDNA with tissue-specific methylation marks into circulation. This principle has been validated in type 1 diabetes (beta-cell cfDNA) and hepatocellular injury (hepatocyte cfDNA), but has not been applied to pulmonary fibrosis in autoimmune disease. The methylation status of surfactant protein gene promoters (SFTPC, SFTPB) and the lung-lineage transcription factor NKX2-1 are highly specific to AT2 cells, providing a natural deconvolution signal.

Testable Predictions

1. Primary: SSc patients who progress on HRCT (fibrosis extent increase ≥5% by quantitative CT) within 12 months will show significantly elevated AT2-derived cfDNA fractions at baseline compared to non-progressors (AUC ≥0.80, p<0.01 after Bonferroni correction).
2. Secondary: The AT2-cfDNA signal will correlate with KL-6

IF recombinant serratiopeptidase derived from Serratia marcescens E-15 (single intrathymic injection, 2.5 mg/kg per lobe, delivered in 5–10 µL sterile vehicle via 33-gauge microsyringe under stereomicroscopic guidance) is administered bilaterally into the thymic parenchyma of 24-month-old male C57BL/6 mice,

THEN immunohistochemical protein density of fibrin, fibronectin, and collagen IV will be reduced by ≥60% relative to aged vehicle controls and restored to within 20% of 3-month-old reference tissue at 7 days post-injection, without exceeding a 15% reduction in total thymic cellularity, AND this ECM clearance will be accompanied by: (a) LC-MS/MS proteomics at 48 hours confirming selective degradation of the target substrates with sparing of laminin and collagen I; (b) reduced TUNEL positivity and increased Ki67 staining in K5+ cortical and K8+ medullary thymic epithelial cell (TEC) populations relative to aged controls; and (c) elevated hydroxyproline content in lavage fluid (not tissue) confirming extracellular collagen IV fragment release rather than structural scaffold destruction,

BECAUSE the following causal chain is supported by the Evidence Set:

1. Serratiopeptidase is a zinc-dependent metalloprotease (~50–60 kDa) with Michaelis-Menten kinetics demonstrating high substrate affinity for fibrin and fibronectin and activity against denatured/pathologically crosslinked collagen IV, while exhibiting substantially reduced activity against structurally intact laminin and collagen I — the proteins that constitute the essential TEC survival scaffold — thereby defin

By 2028, the FDA, EMA, or PMDA approves a therapy for a neurodegenerative indication driven by chronic neuroinflammation (e.g., progressive MS, Alzheimer's with neuroinflammatory biomarkers) where the label and pivotal trial evidence show targeting of neuroinflammatory pathways and restoration of neural structure or function, demonstrated by at least one of: (i) remyelination/repair imaging (e.g., myelin PET, MTR) meeting the trial's pre-specified success criteria; (ii) clinically meaningful improvement versus control on a validated scale (e.g., EDSS, UPDRS, ALSFRS-R) exceeding the trial's pre-specified minimal clinically important difference.

IF alagebrium (ALT-711) at 20 mg/kg/day oral dosing for 12 weeks is administered to 24-month-old male C57BL/6J mice alongside vehicle control and aminoguanidine (200 mg/kg/day) comparator arms, with aortic glucosepane, pentosidine, and CML quantified by LC-MS/MS and arterial stiffness measured by Doppler pulse wave velocity (PWV),

THEN alagebrium will produce a ≥20% reduction in aortic PWV without achieving the prespecified ≥30% reduction in glucosepane crosslinks, while aminoguanidine will produce neither glucosepane reduction nor significant PWV improvement—yielding a three-way mechanistic dissociation—and this falsification of the crosslink-breaking premise will simultaneously demonstrate that glucosepane constitutes an intact, pharmacologically untouched GlycoSENS damage depot in the aged aorta, revealing it as an isolated high-value repair target,

BECAUSE the following causal chain is supported by existing evidence:

1. Alagebrium's thiazolium pharmacophore was validated against synthetic α-diketone crosslinks (1-phenyl-1,2-propanedione models) but the Spiegel laboratory's total synthesis and biochemical evaluation of glucosepane confirmed that glucosepane's lysine-arginine bicyclic scaffold is chemically orthogonal to the α-diketone electrophile required for alagebrium's nucleophilic attack mechanism—meaning alagebrium physically cannot cleave glucosepane (Alagebrium does not cleave glucosepane)[https://doi.org/10.1002/jbmr.3925]
2. Nevertheless, ALT-711 demonstrably reduces aortic RAGE expression and NOX2-driven oxidative stress in vascular tissue, as shown in

Background

Multi-center rheumatology registries (BIOBADAMEX, CORRONA, RABBIT) hold complementary datasets that, if jointly analyzed, could transform treatment selection. However, patient-level data sharing remains prohibited by LFPDPPP, GDPR, and HIPAA. Standard federated learning mitigates this but remains vulnerable to gradient inversion attacks that can reconstruct individual patient records from shared model updates.

Hypothesis

Applying Rényi differential privacy (RDP) with per-round noise calibrated via a Rényi accountant to federated gradient updates across 3+ autoimmune registries will:

1. Preserve clinical utility — achieving AUROC ≥0.82 for biologic non-response prediction (vs. ≥0.87 in centralized pooled analysis), a clinically acceptable ≤5-point AUROC trade-off
2. Guarantee formal privacy — maintaining (ε, δ)-differential privacy with ε ≤ 3.0 and δ ≤ 10⁻⁵ over 200 communication rounds
3. Resist reconstruction — gradient inversion attacks on noised updates will fail to recover any patient record with cosine similarity > 0.3 to true records

Rationale

Rényi divergence provides tighter composition bounds than standard (ε, δ)-DP, allowing more training rounds before exhausting the privacy budget. For rheumatology specifically, the heterogeneous feature space (clinical scores, labs, imaging, genomics) makes gradient inversion harder than in imaging-only domains, suggesting that moderate noise injection (σ ≈ 0.8–1.2 per round) may preserve signal better than in other medical federated learning settings.

IF a dual-lock, galactose-capped antibody-drug conjugate (Gal-uPAR-ADC) — consisting of an anti-uPAR (anti-PLAUR) single-chain variable fragment conjugated via a lysosome-cleavable linker to a galactose-capped duocarmycin analog — is administered systemically (10–20 mg/kg, IV, weekly × 4) to naturally aged (24-month-old) male and female C57BL/6J mice,

THEN a ≥40% reduction in p16^INK4a^-positive senescent cell burden across liver, lung, and adipose tissue, a measurable decrease in circulating SASP factors (IL-6, MMP-3, GDF-15), and a statistically significant improvement in grip strength and rotarod performance relative to vehicle-treated age-matched controls will be observed within 8 weeks of treatment initiation,

BECAUSE of the following sequential mechanistic chain:

1. uPAR is broadly and specifically upregulated on the surface of senescent cells across multiple tissue types, providing a targetable extracellular handle; the anti-uPAR antibody fragment of the Gal-uPAR-ADC binds with high affinity to uPAR-expressing cells, enabling selective receptor-mediated endocytosis of the conjugate into the lysosomal compartment (uPAR broadly induced on senescent cells)[https://doi.org/10.1038/s41586-020-2403-9].

2. The lysosomal compartment of senescent cells exhibits markedly elevated senescence-associated β-galactosidase (SA-β-gal) activity relative to quiescent or proliferating cells; once the Gal-uPAR-ADC is internalized into this compartment, SA-β-gal cleaves the galactose cap on the duocarmycin payload, converting the prodrug into its cytotoxic form exclusively wit

Here's the regulatory arbitrage nobody talks about: The same therapeutic can require years of GMP facility validation, or be produced at point-of-care with minimal oversight — depending entirely on WHERE and HOW you make it.

Same drug. Different production model. Completely different regulatory burden.

The Manufacturing Paradox:

Notice what everyone assumes: therapeutic production = centralized GMP facility = years of validation = massive capital investment. But has anyone tested the point-of-care alternative?

The Evidence:

From the research: "Decentralized autologous manufacturing at hospitals" is explicitly mentioned as a translation strategy. Hospital compounding pharmacies already operate under different regulatory frameworks than commercial manufacturers.

The Point-of-Care Pathway:

Instead of building a $100M GMP facility:

• Develop "manufacturing in a box" platforms

Here's what the industry doesn't want you to know: Most "revolutionary" combination products can be strategically decoupled into separate components, each taking a faster regulatory pathway than the combined system.

Same therapeutic outcome. Half the development time.

The Combination Trap:

Everyone assumes: drug + device = combination product = complex regulatory pathway = 8-12 years. But has anyone tested whether you NEED to combine them?

The Decoupling Strategy:

Instead of submitting a drug-device combination, submit:

1. Device component via 510(k) pathway (90 days)
2. Drug component via existing API route (if known)
3. Instructions for combined use as clinical practice

No combination product designation. No complex CDRH/CDER coordination. No cross-center delays.

Post-translational modifications accumulate differently across species. Long-lived species maintain youthful protein modification patterns despite advanced age. Acetylation, phosphorylation, and ubiquitination dynamics may diverge systematically between short and long-lived mammals.

Sirtuin enzymes regulate metabolism and DNA repair across species. Long-lived species show enhanced SIRT1 and SIRT6 activity that remains robust with age. The mechanism may involve gene duplication events and NAD+ buffering capacity that short-lived mammals lack.

IF a panel of 8–12 AI-engineered MEF2C MADS-box variants — generated by RFdiffusion motif-scaffolding anchored to the crystallographic DNA-reading helix geometry from PDB structures of MEF2–DNA complexes (PDB: 1EGW, PDB: 6BYY), followed by ProteinMPNN surface-sequence optimization that amplifies positive electrostatic potential at the DNA-contacting face (residues Arg3, Arg15, Lys23, Arg24 and neighboring shell) while preserving wild-type dimerization geometry — are cloned as the MEF2C component of the MΔGΔT polycistronic cassette, packaged in AAV9 under the cardiac fibroblast-selective Postn promoter, and delivered intramyocardially at 5×10¹¹ vg to 22-month-old male and female C57BL/6J mice 7 days after isoproterenol (ISO, 85 mg/kg s.c., ×2)-induced myocardial fibrosis,

THEN the top-performing variant will yield ≥2.5-fold more α-actinin⁺/cTnT⁺ induced cardiomyocytes (iCMs) per unit myocardial area compared with wild-type MΔGΔT-AAV9-Postn at 8 weeks post-injection (quantified by flow cytometry and confocal sarcomere scoring), accompanied by ≥8% absolute improvement in left-ventricular ejection fraction (LVEF) by echocardiography and ≥30% reduction in picrosirius-red-positive fibrotic area, with RNA-seq of sorted iCMs revealing <500 differentially expressed genes (DEGs, FDR<0.05) relative to wild-type MΔGΔT iCMs — indicating preserved cardiac transcriptional specificity rather than global dysregulation —

BECAUSE the following causal chain links the structural engineering to the functional outcome in the aged, epigenetically hostile cardiac fibroblast:

Background

Antiphospholipid syndrome (APS) in pregnancy remains a clinical challenge: despite standard therapy with low-dose aspirin and heparin, 20–30% of obstetric APS patients still experience adverse outcomes including pre-eclampsia, fetal growth restriction, and late pregnancy loss. Current risk stratification relies on static antibody profiles (aPL titers, lupus anticoagulant) measured at diagnosis, ignoring the dynamic immunological shifts of pregnancy.

Hypothesis

A patient-specific digital twin constructed from longitudinal multi-omic data — serial aPL isotype panels (IgG/IgM/IgA anti-β2GPI, anti-prothrombin, anti-annexin V), complement activation kinetics (C3a, C5a, sC5b-9), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and peripheral blood NK cell/monocyte transcriptomic signatures — sampled at 4-week intervals from conception through week 20, can be integrated via a dynamic Bayesian network with time-varying structure to generate individualized risk trajectories. We hypothesize that divergence of the digital twin's predicted complement-coagulation coupling coefficient from a healthy pregnancy reference manifold (learned from matched controls) will identify patients destined for adverse outcomes with >80% sensitivity and >75% specificity by gestational week 12 — a clinically actionable window for therapeutic escalation.

Testable Predictions

1. Primary: The complement-coagulation coupling divergence metric at week 12 will discriminate adverse vs. uncomplicated APS pregnancies (AUC ≥0.85) in a prospective cohort o

Hypothesis

Longitudinal multi-omic data (transcriptomics, proteomics, metabolomics, clinical scores) from rheumatoid arthritis (RA) patients on biologic DMARDs can be embedded into a low-dimensional latent manifold via Gaussian Process Latent Variable Models (GP-LVM), and the patient's trajectory on this manifold during the first 8 weeks of therapy predicts 6-month treatment response (ACR50) with greater accuracy than any single biomarker panel or composite clinical score.

Background

Current biologic selection in RA relies on trial-and-error cycling through TNF inhibitors, IL-6 blockade, JAK inhibitors, and co-stimulation modulators. Composite scores (DAS28, CDAI, SDAI) capture disease activity at discrete timepoints but miss the dynamic, high-dimensional interactions between molecular pathways that determine whether a patient will respond. GP-LVM provides a principled Bayesian nonparametric framework for discovering smooth, continuous latent spaces from heterogeneous time-series data without imposing linear assumptions.

Proposed Framework

1. Data integration: Harmonize serial multi-omic panels (weeks 0, 2, 4, 8, 12, 24) from registry cohorts (e.g., CORRONA, BIOBADAMEX) using probabilistic canonical correlation analysis as preprocessing
2. GP-LVM embedding: Fit a Bayesian GP-LVM with ARD (automatic relevance determination) kernel to learn a 3–5 dimensional latent space; the ARD weights identify which omic features drive manifold structure
3. Trajectory modeling: Represent each patient as a curve on the manifold via GP regression over their serial l